SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-22-012779
Filing Date
2022-05-11
Accepted
2022-05-11 08:15:55
Documents
53
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 859109
2 ex31-1.htm EX-31.1 18218
3 ex31-2.htm EX-31.2 18243
4 ex32-1.htm EX-32.1 6241
5 ex32-2.htm EX-32.2 6412
  Complete submission text file 0001493152-22-012779.txt   4657876

Data Files

Seq Description Document Type Size
6 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lixt-20220331.xsd EX-101.SCH 39297
7 INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT lixt-20220331_cal.xml EX-101.CAL 31785
8 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT lixt-20220331_def.xml EX-101.DEF 201550
9 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lixt-20220331_lab.xml EX-101.LAB 327061
10 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lixt-20220331_pre.xml EX-101.PRE 254701
47 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 682973
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

IRS No.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39717 | Film No.: 22912157
SIC: 2834 Pharmaceutical Preparations